Clinical Trial

Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas (TORNADO)

Study acronym: TORNADO
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Multicenter, prospective, open-labeled, 2-arm, non-comparative randomized phase II trial to assess the antitumor activity of retifanlimab (INCMGA00012) in association with neoadjuvant chemotherapy
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2021-07-13; most recent amendment 2026-04-20.
Status change: Recruiting → Active, Not Recruiting 2026-04-20
Status change: Not Yet Recruiting → Recruiting 2022-10-04
Trial Details
NCT Number NCT04968106
Lead Sponsor Institut Bergonié
Collaborators: Incyte Biosciences International Sàrl
Conditions Resectable Sarcoma
Enrollment 66 participants
Start Date 2022-12-07
Primary Completion 2025-08-06 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2026-04-21